协同和拮抗的急性髓系白血病细胞类型对5-氮杂-2'-脱氧胞苷和1-β-D-阿拉伯呋喃糖基胞嘧啶的特异性反应。

Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside.

作者信息

Elmoneim Abeer Abd, Heuston Elisabeth, Wai Daniel H, Triche Timothy, Arceci Robert J

机构信息

Pediatric Department, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, U.S.A. Pediatric Department, Taibah University, Madina, Kingdom of Saudi Arabia

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, U.S.A.

出版信息

Anticancer Res. 2016 Feb;36(2):691-6.

DOI:

PMID:26851026

Abstract

BACKGROUND

The search for synergistic drug combinations is critical to the treatment of drug-resistant cancer, such as acute myeloid leukemia (AML). Characterizing RNA expression associated with 5-aza-2'-deoxycytidine (DAC) and 1-h-D-arabinofuranosylcytosine (Ara-C) is a critical step to increase the efficacy of their combinatorial therapies.

MATERIALS AND METHODS

After 72 h of single-dose treatments of AML cells with DAC or Ara-C, the half-maximal effective concentration of DAC and Ara-C and the drug combination index were assessed.

RESULTS

Pre-treatment with DAC restores cellular sensitivity in Ara-C-resistant AML cells. In contrast, DAC/Ara-C combinations are antagonistic in other Ara-C-sensitive AML cells.

CONCLUSION

Our results provide an alternative approach for predicting what combinations, dosing and scheduling of drug delivery should be used to better individualize therapy of AML.

摘要